{"id":60488,"date":"2024-12-13T01:03:37","date_gmt":"2024-12-13T00:03:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/"},"modified":"2024-12-13T01:03:37","modified_gmt":"2024-12-13T00:03:37","slug":"alpha-cognition-announces-voluntary-delisting-from-cse","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/","title":{"rendered":"Alpha Cognition Announces Voluntary Delisting from CSE"},"content":{"rendered":"
\n

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) <\/b>(\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), announces that in connection with the Company\u2019s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company\u2019s common shares will continue to trade on the Nasdaq under the symbol \u201cACOG\u201d.<\/p>\n

\nAbout Alpha Cognition Inc.<\/b><\/p>\n

\nAlpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer\u2019s disease and Cognitive Impairment with mild Traumatic Brain Injury (\u201cmTBI\u201d), for which there are currently no approved treatment options.<\/p>\n

\nZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer\u2019s disease, with expected minimal gastrointestinal side effects. ZUNVEYL\u2019s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer\u2019s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.<\/p>\n

\nForward-looking Statements: <\/i>This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information:
\n
Michael McFadden, CEO
\n
Tel: 1-858-344-4375
\n
info@alphacognition.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), announces that in connection with the Company\u2019s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60488","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), announces that in connection with the Company\u2019s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-13T00:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alpha Cognition Announces Voluntary Delisting from CSE\",\"datePublished\":\"2024-12-13T00:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/\"},\"wordCount\":414,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241212186439\\\/en\\\/2331436\\\/22\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/\",\"name\":\"Alpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241212186439\\\/en\\\/2331436\\\/22\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"datePublished\":\"2024-12-13T00:03:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241212186439\\\/en\\\/2331436\\\/22\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241212186439\\\/en\\\/2331436\\\/22\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-announces-voluntary-delisting-from-cse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha Cognition Announces Voluntary Delisting from CSE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/","og_locale":"en_US","og_type":"article","og_title":"Alpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend","og_description":"VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), announces that in connection with the Company\u2019s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/","og_site_name":"Pharma Trend","article_published_time":"2024-12-13T00:03:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alpha Cognition Announces Voluntary Delisting from CSE","datePublished":"2024-12-13T00:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/"},"wordCount":414,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/","url":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/","name":"Alpha Cognition Announces Voluntary Delisting from CSE - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","datePublished":"2024-12-13T00:03:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241212186439\/en\/2331436\/22\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-announces-voluntary-delisting-from-cse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alpha Cognition Announces Voluntary Delisting from CSE"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60488"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60488\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}